SHetA2
Based on 1 Customer Validation
SHetA2 is a derivative of heteroarotinoid, that exhibits cytotoxicity in cancer cells with IC50 of 0.37–4.6 μM. SHetA2 regulates cancer cells differentiation, induces apoptosis through the intrinsic mitochondrial pathway, and arrest cell cycle at G2 phase. SHetA2 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice. SHetA2 is orally active.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.7%
- No. CAS: 361483-66-1
- Fòrmula: C20H23N3O2S2
- Peso molecular:401.55
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Ver todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
2.98 μM
Compound: 5, SHetA2
|
Growth inhibition of human A2780 cells after 72 hrs by MTS dye based cell titer-96 non-rad cell proliferation assay
Growth inhibition of human A2780 cells after 72 hrs by MTS dye based cell titer-96 non-rad cell proliferation assay
|
[PMID: 25880346] |
| A2780 | IC50 |
3.17 μM
Compound: 1; SHetA2, NSC-721689
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell growth after 72 hrs by CellTiter 96 Non-Rad cell proliferation assay kit method
Antiproliferative activity against human A2780 cells assessed as reduction in cell growth after 72 hrs by CellTiter 96 Non-Rad cell proliferation assay kit method
|
[PMID: 30878829] |
| A2780 | IC50 |
3.17 μM
Compound: NSC 721689, SHetA2; 1
|
Growth inhibition of human A2780 cells after 72 hrs by CellTiter-96 assay
Growth inhibition of human A2780 cells after 72 hrs by CellTiter-96 assay
|
[PMID: 30245396] |
| A2780 | IC50 |
3.17 μM
Compound: SHetA2; NSC 721689
|
Antiproliferative activity against human A2780 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter 96 non-radioactive cell proliferation assay
Antiproliferative activity against human A2780 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter 96 non-radioactive cell proliferation assay
|
[PMID: 31831296] |
| DU-145 | GI50 |
3.47 μM
Compound: SHetA2
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| DU-145 | GI50 |
4.9 μM
Compound: SHetA2
|
Growth inhibition of human DU145 cells
Growth inhibition of human DU145 cells
|
[PMID: 25701251] |
| LNCaP | GI50 |
2.25 μM
Compound: SHetA2
|
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| MCF7 | GI50 |
4.13 μM
Compound: SHetA2
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| MCF7 | GI50 |
4.5 μM
Compound: SHetA2
|
Growth inhibition of human MCF7 cells
Growth inhibition of human MCF7 cells
|
[PMID: 25701251] |
| MDA-MB-453 | GI50 |
3.27 μM
Compound: SHetA2
|
Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| MDA-MB-453 | GI50 |
5 μM
Compound: SHetA2
|
Growth inhibition of human MDA-MB-453 cells
Growth inhibition of human MDA-MB-453 cells
|
[PMID: 25701251] |
| PC-3 | GI50 |
4.8 μM
Compound: SHetA2
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| PC-3 | GI50 |
5 μM
Compound: SHetA2
|
Growth inhibition of human PC3 cells
Growth inhibition of human PC3 cells
|
[PMID: 25701251] |
| T47D | GI50 |
3.99 μM
Compound: SHetA2
|
Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25701251] |
| T47D | GI50 |
4.8 μM
Compound: SHetA2
|
Growth inhibition of human T47D cells
Growth inhibition of human T47D cells
|
[PMID: 25701251] |
Chemical Information
-
No. CAS 361483-66-1
-
Appearance Solid
-
Peso molecular 401.55
-
Fòrmula C20H23N3O2S2
-
Color White to yellow
-
SMILES
S=C(NC1=CC=C([N+]([O-])=O)C=C1)NC2=CC3=C(SC(C)(CC3(C)C)C)C=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureza y Documentación
-
Ficha de datos (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Zhang Y, et al., High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemother Pharmacol. 2006 Nov;58(5):561-9. [Content Brief]
[2]. Benbrook DM, et al., Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct;23(5):417-28. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)